Sino Biopharmaceutical Ltd (HK:1177)
:1177
Want to see HK:1177 full AI Analyst Report?
1177 Stock Chart & Stats
HK$6.00
-HK$0.02(-0.67%)
At close: 4:00 PM EST
HK$6.00
-HK$0.02(-0.67%)
Day’s Range― - ―
52-Week RangeHK$4.39 - HK$9.12
Previous CloseN/A
Volume63.93M
Average Volume (3M)114.93M
Market Cap
HK$83.80B
Enterprise ValueHK$85.73B
Total Cash (Recent Filing)HK$19.82B
Total Debt (Recent Filing)HK$11.96B
Price to Earnings (P/E)31.1
Beta0.88
Next Earnings
Aug 26, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield1.4%
Share Statistics
EPS (TTM)0.21
Shares Outstanding18,705,018,000
10 Day Avg. Volume98,005,928
30 Day Avg. Volume114,926,811
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.44Price Target Upside40.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.23
Revenue Forecast (FY)HK$35.89B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSino Biopharmaceutical's persistently high gross margins (near 78%–83%) indicate strong product-level pricing power and manufacturing efficiency. This durable margin structure supports sustained operating profitability across product cycles, enabling investment in R&D and commercial expansion even if SG&A fluctuates.
Re-accelerating Revenue MomentumRevenue re-acceleration in 2025 signals improving demand and successful commercial execution across franchises. Durable top-line momentum helps absorption of fixed costs, supports longer-term forecasting, and increases runway for new launches and lifecycle extensions versus a flat-growth profile.
Healthy Cash GenerationImproved operating and free cash flow, with FCF near 0.82x of net income, demonstrates solid cash conversion and earnings quality. Strong cash generation underpins capital allocation flexibility for R&D, debt servicing, or M&A and reduces reliance on external funding over a multi‑quarter horizon.
Bears Say
Declining Net MarginA material fall in net margin reduces earnings resilience and indicates rising non‑gross costs or one‑off pressures. If sustained, lower net profitability constrains free cash flow expansion and weakens return metrics, making funding of R&D or debt repayment more challenging over several quarters.
Rising LeverageMeaningful increase in debt-to-equity reflects a less conservative capital structure and reduces financial flexibility. Higher leverage elevates interest and refinancing risk, limiting the firm's ability to absorb profit volatility or fund strategic initiatives without increasing cost of capital over the medium term.
Modest Cash Coverage Vs Operating ProfitA low coverage ratio (~0.37) means operating profit does not fully convert to cash in the near term, likely due to working capital or noncash adjustments. This magnifies sensitivity to receivables or inventory swings and can strain liquidity if earnings weaken or if seasonal working capital demands rise.
Sino Biopharmaceutical News
1177 FAQ
What was Sino Biopharmaceutical Ltd’s price range in the past 12 months?
Sino Biopharmaceutical Ltd lowest stock price was HK$4.39 and its highest was HK$9.12 in the past 12 months.
What is Sino Biopharmaceutical Ltd’s market cap?
Sino Biopharmaceutical Ltd’s market cap is HK$83.80B.
When is Sino Biopharmaceutical Ltd’s upcoming earnings report date?
Sino Biopharmaceutical Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 72 days.
How were Sino Biopharmaceutical Ltd’s earnings last quarter?
Sino Biopharmaceutical Ltd released its earnings results on Mar 26, 2026. The company reported HK$0.011 earnings per share for the quarter, missing the consensus estimate of HK$0.069 by -HK$0.057.
Is Sino Biopharmaceutical Ltd overvalued?
According to Wall Street analysts Sino Biopharmaceutical Ltd’s price is currently Undervalued.
Does Sino Biopharmaceutical Ltd pay dividends?
Sino Biopharmaceutical Ltd pays a Quarterly dividend of HK$0.05 which represents an annual dividend yield of 1.4%. See more information on Sino Biopharmaceutical Ltd dividends here
What is Sino Biopharmaceutical Ltd’s EPS estimate?
Sino Biopharmaceutical Ltd’s EPS estimate is 0.14.
How many shares outstanding does Sino Biopharmaceutical Ltd have?
Sino Biopharmaceutical Ltd has 18,705,018,000 shares outstanding.
What happened to Sino Biopharmaceutical Ltd’s price movement after its last earnings report?
Sino Biopharmaceutical Ltd reported an EPS of HK$0.011 in its last earnings report, missing expectations of HK$0.069. Following the earnings report the stock price went down -1.855%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:1177
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sino Biopharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$8.44 (40.71% Upside)
HK$8.44 (40.71% Upside)
Insider Transactions
Bought Shares
Worth HK$68.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.30%
12-Months-Change
Fundamentals
Return on Equity
7.24%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Sino Biopharmaceutical Ltd
Established in 2000 and headquartered in Wan Chai, Hong Kong, Sino Biopharmaceutical Limited functions as an investment holding entity overseeing a prominent research and development-focused pharmaceutical conglomerate. Its core operations are primarily situated within the People's Republic of China, segmented into three main areas: modern and traditional Chinese medicines and chemical pharmaceuticals, investment ventures, and other diverse activities. The company maintains an extensive portfolio of pharmaceutical products addressing numerous therapeutic categories. This includes oncology treatments such as Qingkeshu tablets and Anxian capsules; cardiovascular and cerebrovascular medications like Kaina and Anrixin tablets; hepatitis remedies, including Tianqingganmei injections; and orthopedic solutions such as Gaisanchun capsules. The product range also covers respiratory system drugs, parenteral nutritional therapies (e.g., Xinhaineng injections), and other miscellaneous medicines like Tuotuo tablets. Furthermore, Sino Biopharmaceutical distributes a selection of advanced pharmaceuticals, including Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond pharmaceutical manufacturing and distribution, the company engages in a broad array of healthcare-related services and investments. These activities encompass managing property assets, retailing and distributing pharmaceutical goods, offering optometry services and selling ophthalmic products, and operating hospitals. It also provides medical management and health information consultancy, bio-tech transfer and advisory services, and manufactures and markets health food products. Additionally, the company performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical glasses, and conducts research, development, and sales of medical devices and active pharmaceutical ingredients.
1177 Stock 12 Month Forecast
Average Price Target
HK$8.44
▲(40.71% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---